Acorda Therapeutics, Inc.
ACORQ
OTC PK
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -352.48% | -283.60% | 84.90% | 82.40% | 38.73% |
| Total Depreciation and Amortization | -23.47% | -3.48% | -3.52% | -5.41% | -4.37% |
| Total Amortization of Deferred Charges | 15.16% | 12.94% | 14.26% | 9.21% | 6.14% |
| Total Other Non-Cash Items | 4,907.38% | 3,189.83% | -263.57% | -250.35% | 62.47% |
| Change in Net Operating Assets | -1,194.88% | -737.87% | -139.65% | -168.07% | -104.53% |
| Cash from Operations | -89.80% | 33.17% | 92.90% | 66.55% | 49.09% |
| Capital Expenditure | -172.16% | -94.12% | -60.58% | 75.45% | 44.89% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 200.00% | -- | -- |
| Cash from Investing | -172.16% | -94.12% | 62.69% | 75.45% | 44.89% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -100.29% | -63.28% | 292.42% | 363.25% | 140.07% |
| Miscellaneous Cash Flow Adjustments | -- | -- | 200.00% | 100.00% | -- |
| Net Change in Cash | -100.11% | 31.57% | 97.84% | 70.60% | 85.87% |
